Clinical Trials
56 trialsDoDNAC
Children's Hospital Medical Center, Cincinnati
SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors
Sarcoma Alliance for Research through Collaboration
NF1NAC
Children's Hospital Medical Center, Cincinnati
Precision Medicine for Neurocutaneous Syndromes in Western China
West China Hospital
Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing
Massachusetts General Hospital
Evaluating Genetic Modifiers of Cutaneous Neurofibromas in Adults With Neurofibromatosis Type 1
Stanford University
Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas
Massachusetts General Hospital
NEF-1
Assistance Publique - Hôpitaux de Paris
Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach.
Corewell Health West
Neurobiology and Treatment of Reading Disability in NF-1
Vanderbilt University
Evaluating Mitochondrial Dysfunction in Patients With Neurofibromatosis Type 1
University of Arkansas
NF108-BINI
University of Alabama at Birmingham
Innovation in the Treatment of Persistent Pain in Adults With NF1: Implementation of the iCanCope Mobile Application- Clinical Trial
Yale University
Clinical Hypnosis and Home Blood Pressure Monitoring in Children With Neurofibromatosis Type 1
Murdoch Childrens Research Institute
Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas
Massachusetts General Hospital
Dosing and Tolerability of Deoxycholic Acid vs. Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas
Massachusetts General Hospital
MicroRNAs in Patients With Neurofibromatosis Type 1
Ann & Robert H Lurie Children's Hospital of Chicago
NF1
University Hospital, Strasbourg, France
Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery
Mayo Clinic
DPCP to Treat Cutaneous Neurofibromas Associated With NF1
Icahn School of Medicine at Mount Sinai
INSPECT
Great Ormond Street Hospital for Children NHS Foundation Trust
DCLNF1
The University of Texas Health Science Center, Houston
OPTIMAL-SSI
Virginia Commonwealth University
Medical Treatment of "High-Risk" Neurofibromas
Corewell Health West
Frameshift Peptides of Children With NF1
Children's National Research Institute
COGTRAIN
Children's National Research Institute
Mechanism of Action of Transcranial Direct Current Stimulation in Neurofibromatosis Type 1
University of Manchester
ASD/NF1inhib
University of Coimbra
Effects of Physical Training on Bone and Muscle Quality, Muscle Strength, and Motor Coordination in Children With NF1
Shriners Hospitals for Children
A Single Center Pilot Study to Assess the Intra-observer Reliability of Measuring Muscle Strength Using a Hand Held Dynamometer in Children and Adults With Neurofibromatosis Type 1 (NF1) and Type 2 (NF2)
NYU Langone Health
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
Northwestern University
Genetic Evaluation of NF1 and Scoliosis Patients
University of Minnesota
tDCS is NF1
University of Manchester
NF1TD
Shriners Hospitals for Children
Multi-center Project: Spinal Abnormalities in Neurofibromatosis Type1 (NF1) Patients
Shriners Hospitals for Children
MEK Inhibitor
University of Alabama at Birmingham
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors
Sarcoma Alliance for Research through Collaboration
Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas
Children's Hospital of Philadelphia
Spine
University of Utah
STARS
University of Alabama at Birmingham
Protocol 102
University of Alabama at Birmingham
Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With NF1
Fundação Educacional Serra dos Órgãos
NF1
University Hospital, Brest
NPRI
Washington University School of Medicine
Neurofibromatosis Type 1 Brain Tumor Genetic Risk
Washington University School of Medicine
Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1
Massachusetts General Hospital
NF1
University of California, Los Angeles
Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1
Massachusetts General Hospital
NF1-QDV
Nantes University Hospital
Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype
Massachusetts General Hospital